Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer

Mutant K-ras activity leads to the activation of the RAS/RAF/MEK/ERK pathway in approximately 44% of colorectal cancer (CRC) tumors. Accordingly, several inhibitors of the MEK pathway are under clinical evaluation in several malignancies including CRC. The aim of this study was to develop and charac...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Tentler, John J., Nallapareddy, Sujatha, Tan, Aik Choon, Spreafico, Anna, Pitts, Todd M., Morelli, M. Pia, Selby, Heather M., Kachaeva, Maria I., Flanigan, Sara A., Kulikowski, Gillian N., Leong, Stephen, Arcarol, John J., Messersmith, Wells A., Eckhardt, S. Gail
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3931013/
https://ncbi.nlm.nih.gov/pubmed/20923857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0376
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares